144 related articles for article (PubMed ID: 16763786)
1. Phase I dose escalation study of pegylated liposomal doxorubicin (Caelyx) in combination with topotecan in patients with advanced malignancies.
Ghesquières H; Faivre S; Djafari L; Pautier P; Lhommé C; Lozahic S; Djazouli K; Armand JP; Raymond E
Invest New Drugs; 2006 Sep; 24(5):413-21. PubMed ID: 16763786
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumors.
Mavroudis D; Kouroussis Ch; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Samonis G; Georgoulias V
Oncology; 2002; 62(3):216-22. PubMed ID: 12065868
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes.
Pentheroudakis G; Briasoulis E; Karavassilis V; Mauri D; Tzamakou E; Rammou D; Pavlidis N
Chemotherapy; 2005 May; 51(2-3):154-61. PubMed ID: 15886476
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of pegylated liposomal doxorubicin (Caelyx) in combination with carboplatin in patients with advanced solid tumors.
Gonçalves A; Braud AC; Viret F; Genre D; Gravis G; Tarpin C; Giovannini M; Maraninchi D; Viens P
Anticancer Res; 2003; 23(4):3543-8. PubMed ID: 12926104
[TBL] [Abstract][Full Text] [Related]
5. Phase I clinical trial of topotecan and pegylated liposomal doxorubicin.
Garcia AA; Roman L; Muderspach L; O'meara A; Facio G; Edwards S; Burnett A
Cancer Invest; 2005; 23(8):665-70. PubMed ID: 16377584
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of liposomal doxorubicin (Doxil) with topotecan.
Ryan CW; Fleming GF; Janisch L; Ratain MJ
Am J Clin Oncol; 2000 Jun; 23(3):297-300. PubMed ID: 10857898
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer.
Mirchandani D; Hochster H; Hamilton A; Liebes L; Yee H; Curtin JP; Lee S; Sorich J; Dellenbaugh C; Muggia FM
Clin Cancer Res; 2005 Aug; 11(16):5912-9. PubMed ID: 16115933
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
Miller AA; Hargis JB; Lilenbaum RC; Fields SZ; Rosner GL; Schilsky RL
J Clin Oncol; 1994 Dec; 12(12):2743-50. PubMed ID: 7527456
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies.
Tolcher AW; O'Shaughnessy JA; Weiss RB; Zujewski J; Myhand RC; Schneider E; Hakim F; Gress R; Goldspiel B; Noone MH; Brewster LR; Gossard MR; Cowan KH
Clin Cancer Res; 1997 May; 3(5):755-60. PubMed ID: 9815746
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer.
Rose PG; Smrekar M; Haba P; Fusco N; Rodriguez M
Am J Clin Oncol; 2008 Oct; 31(5):476-80. PubMed ID: 18838885
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of Caelyx (doxorubicin HCL, pegylated liposomal) in recurrent or metastatic head and neck cancer.
Caponigro F; Comella P; Budillon A; Bryce J; Avallone A; De Rosa V; Ionna F; Comella G
Ann Oncol; 2000 Mar; 11(3):339-42. PubMed ID: 10811502
[TBL] [Abstract][Full Text] [Related]
12. A phase I clinical trial of topotecan given every 2 weeks in patients with refractory solid tumors.
Kakolyris S; Kouroussis C; Souglakos J; Mavroudis D; Agelaki S; Kalbakis K; Androulakis N; Vardakis N; Vamvakas L; Georgoulias V
Oncology; 2001; 61(4):265-70. PubMed ID: 11721172
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer.
Herben VM; Panday VR; Richel DJ; Schellens JH; van der Vange N; Rosing H; Beusenberg FD; Hearn S; Doyle E; Beijnen JH; ten Bokkel Huinink WW
J Clin Oncol; 1999 Mar; 17(3):747-55. PubMed ID: 10071262
[TBL] [Abstract][Full Text] [Related]
14. A dose escalation study of pegylated liposomal Doxorubicin (caelyx) in combination with capecitabine (xeloda) in patients with refractory solid tumors.
Maltezos E; Amarantidis K; Trichas M; Vasiliadis M; Toromanidou M; Chatzaki E; Karayiannakis A; Tsaroucha A; Romanidis K; Kakolyris S
Oncology; 2005; 69(6):463-9. PubMed ID: 16374040
[TBL] [Abstract][Full Text] [Related]
15. A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors.
Seiden MV; Ng SW; Supko JG; Ryan DP; Clark JW; Lynch T; Huang KC; Kwiatkowski D; Skarin A; Eder JP
Clin Cancer Res; 2002 Mar; 8(3):691-7. PubMed ID: 11895897
[TBL] [Abstract][Full Text] [Related]
16. Prolonged infusional topotecan and accelerated hyperfractionated 3d-conformal radiation in patients with newly diagnosed glioblastoma--a phase I study.
Grabenbauer GG; Anders K; Fietkau RJ; Klautke G; Feldmann HJ; Weiser S; Staab HJ; Krauseneck P; Sauer R
J Neurooncol; 2002 Dec; 60(3):269-75. PubMed ID: 12510778
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of weekly paclitaxel and liposomal doxorubicin in patients with advanced solid tumours.
Androulakis N; Kouroussis C; Mavroudis D; Kakolyris S; Souglakos J; Agelaki S; Kalbakis K; Malas K; Pallis A; Samonis G; Georgoulias V
Eur J Cancer; 2002 Oct; 38(15):1992-7. PubMed ID: 12376203
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study.
Lilenbaum RC; Miller AA; Batist G; Bernard S; Hollis DR; Rosner GL; Egorin MJ; Schilsky RL; Ratain MJ
J Clin Oncol; 1998 Oct; 16(10):3302-9. PubMed ID: 9779705
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of escalating doses of topotecan in combination with a fixed dose of pegylated liposomal doxorubicin in women with müllerian malignancies.
Penson RT; Seiden MV; Goodman A; Fuller AF; Berkowitz RS; Matulonis UA; Krasner C; Lee H; Atkinson T; Campos SM;
Gynecol Oncol; 2004 Jun; 93(3):702-7. PubMed ID: 15196868
[TBL] [Abstract][Full Text] [Related]
20. Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies.
Posey JA; Wang H; Hamilton J; Delgrosso A; Zhang R; Freda T; Zamboni WC
Cancer Chemother Pharmacol; 2005 Aug; 56(2):182-8. PubMed ID: 15838660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]